Drugs / JNJ-95298177
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07082920 | Jul 2025 → Jan 2027 expected | prostate neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-95298177 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07082920 ↗ |
| Modality | Other / unclassified | “Antibody Drug Conjugate” NCT07082920 ↗ |
| Route | Intravenous | “JNJ-95298177 will be administered intravenously.” NCT07082920 ↗ |